

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Limited Research Investigating the Added Value of MRI in Predicting Future Cognitive Morbidity in Survivors of Paediatric Brain Tumours: A Call to Action for Clinical Neuroimaging Researchers

Griffiths-King, D.¹, Delivett, C.¹, Peet, A.^{2,3}, Waite, J.¹ & Novak, J.¹

¹ Aston Institute of Health and Neurodevelopment, College of Health and Life Sciences, Aston University, Birmingham, B4 7ET, UK

² Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2SY, UK

³ Birmingham Women’s and Children’s Hospital NHS Foundation Trust, Birmingham B15 2TG, UK

Correspondence to: Dr Jan Novak (email: j.novak@aston.ac.uk)

ORCID

Griffiths-King, D. - <https://orcid.org/0000-0001-5797-9203>

Delivett, C. - NA

Peet, A. - NA

Waite, J. - <https://orcid.org/0000-0002-8676-3070>

Novak, J. - <https://orcid.org/0000-0001-5173-3608>

Abstract

Survivors of paediatric brain tumour patients are at high risk of cognitive morbidity. There is clinical benefit in being able to reliably predict, at the individual patient level, whether a patient will experience these difficulties or not, the degree of impairment, and the domains affected. Whilst established risk factors exist, quantitative analysis of MRI could provide added predictive value towards this goal, above and beyond existing clinical risk models. The current systematic review aims to answer the question “Do MRI markers predict future cognitive functioning in paediatric brain tumour survivors?”. Studies of paediatric brain tumour patients which test the value of MRI variables in predicting later neuropsychological outcomes were searched up to July 2022. Only included were studies where MRI scans were acquired at an earlier timepoint and used to predict a child's performance on cognitive tests at a later timepoint. Surprisingly few studies were identified by the search process which specifically investigated MRI measures of cerebellar and white matter damage as features in predicting cognitive outcomes. However, the important finding of this review is that the current literature is limited and those identified had small sample sizes and were rated as poor quality for the purposes of prediction. Overall, current findings are at high risk of bias and thus the quality and impact of conclusions are limited. Given the significant impact for this clinical population that predictive models would enable, the current review affirms the need for a ‘call to action’ for medical imaging researchers in paediatric neuro-oncology.

Keywords: MRI, neuropsychology outcomes, prediction, Brain Tumour, children

35 **Introduction**

36 *Individual Outcomes for Childhood Brain Tumour Patients*

37 Survival from cancer in childhood has seen great improvement in recent decades [1]. Consequently, there is a large and increasing
38 population of adult survivors of childhood cancers [1, 2], with approximately 1 in 530 young adults between the ages of 20 and 39
39 being a survivor of childhood cancer [3]. This is especially true in pediatric brain tumours, the most common solid tumours in
40 children (roughly 20%) [4], where survival is now estimated at around 95% for cerebellar pilocytic astrocytoma, and 60-80% for
41 medulloblastoma [5-8]. Thus, there is an ever increasing need to focus on ensuring quality of life for the future of these children.

42 Many children with brain tumours experience neurocognitive effects at some point in their disease course, resulting in dysfunction
43 in domains of cognition, emotion, and behaviour. The estimated risk for children with brain tumours of having emotional,
44 psychosocial, and attention problems are 15%, 12% and 12% respectively, according to a recent meta-analysis [9]. Even at 10-
45 year survival, these patients still demonstrate neuropsychological and psychosocial impairment across multiple domains [10].
46 Performance over time demonstrates an inability to acquire new skills and cognitive abilities at the same rate as healthy peers of
47 the same age, rather than a loss of previously acquired abilities [11]. This may explain why these difficulties are likely to persist
48 long-term and are non-transient. The number of post-cancer life-years is much greater for pediatric rather than adult survivors, and
49 these years include numerous important milestones such as education and interpersonal relationship development [12]. Long-term
50 difficulties are likely to profoundly affect participation for these children, at home, school and later in the workplace, likely
51 resulting in poorer long-term educational and employment outcomes [13, 14]. This results in persistent burden for families and
52 healthcare systems [15]. Whilst survival must always be the utmost priority, research aimed at limiting this cognitive morbidity in
53 this group is now needed to ensure likelihood of reaching their potential, despite their illness [16].

54 Whilst disease and treatment will inevitably place all pediatric brain tumour patients at some level of risk for poor cognitive
55 outcomes, knowing individualised risk at the patient level, an estimate of the severity of difficulties they will face, and the specific
56 domains that are likely to be impacted, will influence clinical practice. There is significant variability in outcomes at the
57 individual patient-level, but this is currently understudied [15]. Person-centred analytical approaches across a large longitudinal
58 sample of paediatric brain tumour patients, show distinct classes / phenotypes with unique profiles in social, cognitive, and
59 attentional difficulties over time [17]. Similar subgroups have been identified across cross-sectional neuropsychological data in
50 pediatric brain tumour patients [18]. Further research is needed to translate this into further individualised models of risk and
51 resilience, for use in clinical settings.

52 *Clinical Benefits from Prediction of Cognitive Outcomes*

53 Prediction of individual-level neurocognitive outcomes would enable timely and tailored input from school and allied health
54 services, promoting outcomes for these children, with limited healthcare resources being efficiently prioritised for those most at
55 risk. It would also help healthcare professionals prepare patients for these difficulties and help reduce uncertainty over the future
56 for families. Children who are undergoing treatment, would also clinically benefit from predictive research for cognitive
57 morbidities. In children where treatment of their brain tumour is more difficult, adjuvant therapy may include radiotherapy, which
58 is known to have significant impact on a child's neurodevelopment. This is due to brain injury from the primary and secondary
59 effects of radiotherapy, especially in paediatrics where there is specific vulnerability (e.g., due to younger children not yet having
60 reached peak myelin maturity) [19, 20]. Whilst developments in treatment have mitigated some risk of neurocognitive toxicity
61 (e.g. proton beam radiotherapy [21]), there is still need for clinicians to make decisions about treatment strategy to further reduce
62 risk to a child's neurocognitive development, using existing disease and age related risk factors [19, 20]. More accurate prediction
63 of individual-level risk of cognitive morbidity (even across domain and severity), would enable clinicians to further adapt and
64 personalise treatment schedules with a greater focus on risk to quality-of-life whilst maintaining efficacy in treating disease [22].
65 Overall, there is clinical benefit for a range of patients in knowing individualised prediction of neurocognitive outcomes.

66 *Predicting Cognitive Outcomes*

67 There are many established risk factors for poor long-term neuropsychological outcome that need to be understood to provide a
68 comprehensive risk profile at the individual child level [23]. Recent neurodevelopmental models based on known risk factors have
69 been proposed to explain outcomes for brain tumour survivors, specifically in medulloblastoma [24-26], taking into consideration
70 the complex disease-, treatment- and host-related factors that may influence these outcomes. Many aspects can result in
71 neurodevelopmental insults to the developing brain which may explain and underpin these neurobehavioral morbidities [27, 28]
72 and thus are significant risk factors for these poor outcomes [23]. These range from physical factors such as treatment effects (i.e.
73 resection and/or adjuvant therapy [19, 29]) and individual differences (i.e. age at diagnosis [29], cognitive reserve), but also
74 psychological factors (i.e. Early Childhood Adversity, threat exposure) and environmental factors (i.e. Socioeconomic Status
75 (SES) and social support) [27]. See [23] for a model of cognitive risk in pediatric brain tumour survivors. Essentially,
76 neurocognitive outcomes are complex and are dependent on several interacting factors [12].

77 Risk-based and exposure-related guidelines and models have been developed to manage these neurocognitive late-effects of
78 pediatric brain tumours [23, 30]. Neurobehavioral morbidities are predicted by clinical variables such as radiotherapy,

39 chemotherapy, neurosurgery, and parental education but less-so age at diagnosis, gender, or time since diagnosis [12, 13, 19, 31-
30 34]. The Neurological Predictor Scale (NPS) was designed as an ordinal scale to capture the cumulative effect of some of these
31 risk factors on outcomes, and somewhat predicts IQ, adaptive functioning and processing speed and working memory, at both
32 short- and long-term follow-up [33, 35-38]. This cumulative measure captures unique variance, above and beyond the individual
33 predictors.

34 *MRI as a Novel Predictor of Outcomes*

35 MRI measures are likely to be a good proxy of the burden of brain tumours and their treatment thus, are likely to be predictive of
36 cognitive impairment at the individual patient-level. Qualitative reporting of MRI does in fact predict outcomes, with brainstem
37 invasion, midline location of the tumour, and tumour type predicting post-operative cerebellar mutism syndrome, a (typically)
38 transient, neurological morbidity seen in this population [39]. Quantitative alterations to the brain's structure and function,
39 specifically microstructural changes to the white matter (WM) of the brain, during the developmental period, could be the
40 common neuroanatomical substrate of these outcomes [24, 26]. See [40] and [22] for a review of MRI in pediatric brain tumours.
41 Recent successes and interest in using MRI to predict neurodevelopmental outcomes in premature infants [41], or even decline in
42 neurocognitive functioning in older adults [42] highlights the potential opportunities offered by MRI in this space. Therefore,
43 magnetic resonance imaging (MRI) is likely to provide highly relevant features which provide 'added-value' in predicting
44 outcomes beyond clinical risk factors alone.

45 A key consideration, however, is the timing of the MRI used to predict these outcomes. The MRI used for prediction needs to be
46 early enough in the disease course and non-contemporaneous from the later, outcome of interest. There is currently no consensus
47 on the optimal timing of MRI with which to make such a prediction. This systematic review specifically investigates existing
48 literature using MRI scans, taken at any point in the disease course, to predict non-contemporaneous, later neuropsychological
49 outcomes in survivors of pediatric brain tumours.

10 Whilst there is existing literature of existing established clinical predictors of cognitive late effects in this population, this review
11 aims to assess studies using MRI as a predictive modality, with the goal of assessing whether quantitative analysis of MRI
12 provides 'added-value' in these risk models.

13 **Method**

14 We conducted this systematic review in accordance with Preferred Reporting Items for Systematic Review and Meta-Analysis
15 (PRISMA) guidelines [43], an overview of which is reported in Figure 1. Initially, a limited search of the Web of Science database
16 was undertaken in June 2022 for the purpose of refining the search terms. Due to the wide-ranging classifications of central
17 nervous system (CNS) tumours, we only used terms pertaining to the most common paediatric histological diagnoses accounting
18 for 85% of total incidence rates (Central Brain Tumour Registry of United States, 2014-2018 [44]). Based on our initial search, we
19 pre-registered our review protocol through the International Prospective Register of Systematic Reviews (PROSPERO) database
20 (registration number CRD42022343161).

21 A comprehensive search of Embase, MEDLINE, PsycINFO, Scopus and Web of Science was conducted in July 2022 using the
22 designed search, resulting in 8,632 records. Minor alterations were made to the search terms for each database to account for
23 differing Boolean operators. Additionally, we also searched the Open Science Framework (OSF) preprints archive for relevant
24 articles that had not otherwise appeared as published texts in our main search. We included any longitudinal study concerning
25 patients diagnosed with a brain tumour before the age of 18, who had MRI data that clearly preceded an age-appropriate,
26 standardised test of cognitive ability (e.g., WISC-V). Central to our main research aim, we included those studies that explicitly
27 reported an association between future cognitive outcomes based on prior MRI. Meta-analyses and literature reviews that did not
28 report new data were excluded, however, reference lists of relevant papers were searched for additional studies of interest. Search
29 results were not restricted by publication date but were limited to those written in English. In addition to our pre-registered
30 exclusion criteria, we also excluded patients with neurofibromatosis, tuberous sclerosis, or acute lymphoblastic leukaemia as these
31 were considered significant confounds for predicting cognitive outcomes. We also excluded non-peer reviewed articles, such as
32 conference abstracts and theses. Inclusion/exclusion criteria are further detailed in Table 1.

Table 1. Inclusion and exclusion criteria for identifying publications for the systematic review

Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none">• Primary CNS tumour• Diagnosis of pediatric brain tumour, between ages of 0-18• Must include brain MRI (of any modality) and age-appropriate, standardised neuropsychological evaluation.• MRI must precede neuropsychological testing, by any period of time.• Report analyses of an association between or prediction of, prospective cognition from MRI.	<ul style="list-style-type: none">• Patient groups where CNS tumours may be present but secondary to other disease (i.e. NFI)• Case studies• Meta-analyses and systematic reviews• Pre-prints where subsequent publication is already included• Not written in English• Conference Abstracts and Theses


-
- Written in English
-

33

34 Identified records were first imported into MS Excel and duplicates removed. Following a short pilot, two independent reviewers
35 (CD + DGK) screened the titles and abstracts of all the identified papers against the inclusion criteria. Full texts of suitable papers
36 were subsequently retrieved and screened by both reviewers for final inclusion in the review. For completeness, we also reviewed
37 the reference lists and citations of those papers marked for inclusion for additional studies that may have been missed. At each
38 stage of the process, disagreements were discussed until a consensus was met. Per our pre-registration, data extraction was
39 completed by one reviewer (DGK), whilst a second reviewer evaluated data extraction of all papers for correctness (JN). The data
40 extraction tool was initially developed for this research protocol and was later refined based upon the findings of the search
41 results. This was not based on an existing tool, and items were selected based on discussion within the research team. Data from
42 each study included: (1) year of publication, (2) study aims and/or hypotheses, (3) study location (i.e., country, recruiting
43 hospital), (4) number of patients, (5) patient characteristics (i.e., years recruited, diagnoses, treatments, cognitive outcomes, age at
44 diagnosis/MRI/neuropsychological evaluation), and (6) statistical analyses.

45 We had initially registered our intention to assess the validity of the included studies using the Transparent Reporting of a
46 multivariate prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines; however, these were deemed
47 unsuitable given that none of the studies reported using predictive modelling in their approach. Instead, studies were reviewed (by
48 DGK) using the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) checklist [45, 46], a checklist for
49 assessing reporting quality specific to the domain of oncology. Whilst designed for marker/assay testing, the domain relevance
50 and prognostic nature renders this a relevant tool. We considered the MRI measures as the ‘marker’ under investigation and the
51 neuropsychological assessment as ‘endpoints’ for the purposes of the tool.

2 Figure 1. PRISMA flow diagram



34 Results

35 After reviewing titles and abstracts, 162 records were selected (see Fig1), and 153 full-text articles were assessed for eligibility.
36 Of those, 4 were included. Manual reference and citation checking of these selected articles (and identified literature reviews
37 deemed to be relevant), identified no additional studies. Detailed information about the included studies can be found in Table 2.

38 Study characteristics and reporting quality

39 Many studies were excluded because the MRI did not precede neuropsychological assessment (for instance because of the
40 matched timepoints of neuroimaging acquisition and test assessment), thus not defining them as 'predictive' studies. In a small
41 number of cases, the text was ambiguous to the order of testing (i.e., [47-50]), but did not refer to prediction, and thus were not
42 included.

43 For the selected studies, sample sizes were small and ranged between $n=7$ and $n=22$. The most common tumour type across
44 studies was medulloblastoma ($n=35$), then astrocytoma ($n=17$) with relatively few ependymoma and choroid plexus papilloma ($n=$
45 3 & 1 respectively). Age at diagnosis across the studies ranged from 2.2 years to 15.6 (based on ranges and inter quartile range
46 (IQR)). All studies selected associative statistical approaches (i.e., correlational analyses).

47 Using the REMARK checklist, studies were assessed against each reporting item (*Item 1-20*), and here we report items where
48 reporting was limited across the studies (i.e. one or less studies reported the item). No studies gave a rationale for sample size
49 (Item 10, 0/4 studies), likely due to the limited samples in each study, however it was unclear as to whether these were the entirety
50 of eligible patients within the given timeframe (as only 1 study gave a full accounting of the flow of patients in the study, *Item 12*,
51 1/4 studies) In terms of "Analysis and presentation", studies performed poorly for a number of items (*Item 15, 17, 18*, all 0/4 with
52 no studies completing the item to be reported). Firstly, no study presented an effect size for the predictive analysis (*Item 15*, 0/4
53 studies). Further, included studies did not conduct analysis of added value, including the MRI marker and 'standard prognostic
54 variables' which are established (*Item 17*, 0/4 studies) nor sensitivity analysis/validation.

55 White Matter (WM) predictors

56 Of the studies assessed, three utilised diffusion tensor imaging (DTI) to image white matter as a predictor of outcomes. Liguoro et
57 al. measured the fractional anisotropy (FA) and volumetry of spinocerebellar (SC), dentorubrothalamicocortical (DRTC) and
58 corticopontocerebellar tracts (frontopontocerebellar (FPC), parieto-pontocerebellar (PPC), occipitopontocerebellar (OPC), and
59 temporo-pontocerebellar (TPC)) [51]. Significant relationships were found between tracts relevant to cerebellar connectivity, and
60 the Developmental Neuropsychology Assessment (NEPSY) and full-scale IQ (FSIQ) measured approximately 5 months later [51].
61 Specifically, FSIQ correlated significantly with spherical and planar indices of the right PPC ($r=-1$, $p=0.017$ and $r=0.886$,
62 $p=0.033$), with increases to planar index and decreases in spherical index associated with IQ [51]. Liguoro et al. also found
63 significant correlations between specific fibre tract characteristics and tasks measuring attention, memory, sensorimotor, social
64 perception, and visuospatial processing domains. However, only visuospatial processing showed convergent validity with
65 significant correlations across two different tasks measuring this same domain [51]. In this study, the bilateral PPC and SC tracts
66 were most commonly correlated with the neuropsychology tasks [51].

67 Partanen et al., used MRI from the treatment period 3 months after diagnosis (including during and after treatment) to predict
68 change in intellectual functioning over a 36 month period after diagnosis. A significant reduction in FSIQ over time was found but
69 this was not related to diffusion measures (FA, mean diffusivity (MD), radial diffusivity (RD) and axial diffusivity (AD)) for the
70 cortical spinal tract (CST), inferior fronto-occipital fasciculus (IFOF), inferior longitudinal fasciculus (ILF), optic radiations (OR),
71 and uncinate fasciculus (UF) [52]. Partanen et al. did however show that declines over time in processing speed index, observed
72 only in a subgroup of patients experiencing local therapy (i.e., focal radiation) versus cranial spinal radiation, was predicted by
73 baseline anisotropy in left inferior fronto-occipital fascicle (IFOF), with lower FA being related to greater decline [52]. Neither
74 patient groups showed a difference in the left IFOF for diffusions measures compared to controls.

75 Riggs et. al. [53] utilised chronically acquired MRI (approximately 5 years post diagnosis) investigated correlations between
76 whole brain WM volume, FA of both the left and right UF and the general memory index of the CMS (in a subset of $n=10$
77 patients, outcomes measured between 2 and 19 months after MRI). Only FA of the left UF was significantly related to memory
78 ($R=.64$, $p=.045$), not the right uncinate fasciculus or total WM volume (as measured by structural MRI), with increased FA related
79 to increases in memory performance. The volume of the PPC tract also positively correlated with memory performance ($R=.71$,
80 $p=.045$) in Parten's study [52].

81 Strength of correlational relationship between indices of white matter integrity and neuropsychological outcome were large
82 (according to Cohen's criteria) ranging from $|r|=.64$ - $|r|=1$. However, the very limited sample sizes ($n=10$ & $n=7$) from which
83 these were drawn gives reason for concern over the interpretation of these estimates.

84 Grey Matter (GM) predictors

35 In Riggs et. al., No correlation was found between total GM volume or left hippocampus with the general memory index of the
36 CMS, but the right hippocampal volume, measured at a chronic timepoint, showed significant positive correlation with memory
37 outcomes 2-19 months after MRI ($R=.71$, $p=.02$) [53]. It is important to note in this study, that the right hippocampus, rather than
38 the GM volume and left hippocampus, was significantly smaller in the patient group compared to healthy controls.

39 **Lesion predictors**

40 Zilli et. al. [54] used a lesion-symptom mapping approach, to investigate the overlap of lesions in children with versus without
41 psychological impairment. The lesions investigated were tumour lesions, frontal insertion of ventriculoperitoneal drainages and
42 ventricular volumes, as drawn on the T1w MRI. They found the greatest tumour lesion overlap and therefore greatest damage was
43 found in median cerebellar, specifically paravermal and vermal regions. Regions of interest for the lateral ventricles also
44 overlapped in impaired children, suggesting hydrocephalus as additional cause of future impairment.

45 **Meta-analysis**

46 Despite registering our intention, reviewed studies were not of sufficient quality to conduct any form of meta-analysis due to
47 varying measurement strategies, gaps in reported descriptive variables, and low power.

Table 2.

Reference	Study Variables				Medical Variables		
	Recruitment Hospital	Years of Recruitment	Number of participants	Healthy controls?	Age at Diagnosis	Tumour Type	Treatment
Zilli et al. [54]	Azienda Sanitaria Universitaria Integrata di Udine, Italy	2012-2019	7 (5 males, 2 females)	NA	Med. 5.3y (IQR 2.2-8.1)	PA n=5, MB n=2	Surgery (7, 100%), Radical surgery (7, 100%), CT (2, 29%), CRT (1, 14%), PT (1, 14%)
Partanen et al. [52]	Hospital for Sick Children, Alberta Childrens Hospital, British Columbia Childrens Hospital, Canada	2007-2011	CSR Group 12 (7 males, 5 females), Local therapy 10 (5 males, 5 females)	24 (12 males, 12 females), Mean age at testing 10.51y (range 5.81-14.93)	CSR Group: Mean 9.32y (sd 2.69, range 5.96-15.26), Local Group: Mean 9.59y (sd 3.62, range 5.77-15.63)	CSR group: MB n=12, Local group: Astrocytoma n=6, EP n=3, Choroid Plexus papilloma (4th Ventricle) n=1	CSR group: surgery (12), CSR (12) and focal radiation to tumour bed (12), chemotherapy (12), Local therapy group: surgery only (7), surgery and focal radiation to the tumour bed (3), chemotherapy (1).
Liguoro et al. [51]	NR	2013-2017	7 (4 males, 3 females)	NA	Med. 63 months (IQR 39-80)	PA n=5, MB n=2	Only surgery (5, 72%), Surgery + RT + CT (2, 28%)
Riggs et al. [53]	Hospital for Sick Children, Alberta Childrens Hospital, British Columbia Childrens Hospital, Canada	2007-2011	20 (13 males, 7 females)	13 (8 males, 5 females), Mean age at test 12.5y (range 8.1-17.2)	Mean 7.2y (range 4.3-12.8)	Recurrent Astrocytoma n=1, MB n=19	surgery (20, 100%), CRT (20, 100%), CT (NR)

N.B. PA = Pilocytic Astrocytoma, MB = Medulloblastoma, CT = Chemotherapy, CRT = Cranial Radiation Therapy, PT = Proton Therapy

8

9

Table 2. (cont.)

Reference	MRI Variables				Neuropsychology Variables			Statistical Variables	
	Age at MRI	MRI Timepoint	Sequence	MRI Measure	Age at Assessment	Measure	Time between MRI and Assessment	Statistical Approach	Statistic of association/prediction
Zilli et al. [54]	NR	Post-surgery	1.5T T1w, T2w, FLAIR	sMRI - VOI of i) lesion, ii) frontal insertion of VPS and iii) ventricular volume, achieved extent of resection.	Med. 7.3y (IQR 6.0-10.8)	NEPSY-II, BVL_4-12	Med. 5.0 months (IQR 0.0 - 11.0)	Lesion symptom mapping	NA
Partanen et al. [52]	CSR Group: Mean 9.59y (sd 2.66, range 6.27-15.41), Local Group: Mean 9.88y (sd 3.65, range 6.01-16.07)	During and Post-Treatment (3m post diagnosis)	1.5T T1w, DTI	dMRI - FA, MD, RD, AD	NR - Multiple assessment timepoints (3, 12, 24, and 36 months post diagnosis),	WISC-IV or WAIS-IV	NR - Multiple assessment timepoints (3, 12, 24, and 36 months post diagnosis),	Correlational analyses	Pearson's r
Liguoro et al. [51]	NR	NR (post-resection)	1.5T T1w, T2w, FLAIR, DTI	Fibre tract volume, FA, RA, SI, PI, LI (cerebellar connections)	Med. 88m (IQR 74.5-129.5)	NEPSY-II WISC-IV	Med. 5m (IQR 0-8.5)	Correlational analyses	Spearman's Rank
Riggs et al. [53]	NR	Chronic post treatment (5yr-post diagnosis)	1.5T T1w, DTI	Whole brain volumes, Unicate Fasciculus (FA), hippocampal volume.	NR	CMS	n=10 assessed, n=7 <2 months of MRI, n=3 <19 months of MRI	Correlational analyses	NR

N.B. PA = Pilocytic Astrocytoma, MB = Medulloblastoma, EP = Ependymoma, CT = Chemotherapy, CRT = Cranial Radiation Therapy, PT = Proton Therapy, NR = Not Reported, sMRI = structural MRI, dMRI = Diffusion MRI, VOI = Volume of Interest, FA = Fractional Anisotropy, MD = Medial Diffusivity, RD = Radial Diffusivity, AD = Axial Diffusivity, Med. = Median, BVL=Battery for the Assessment of Language in Children aged 4-12, CMS = Children's Memory Scale, CSR=Cranial-Spinal Radiation

51 Discussion

52 Review of the State of Research

53 The current systematic review aimed to investigate existing literature using MRI to predict later, and non-contemporaneous
54 neuropsychological outcomes in children with brain tumours. No studies reviewed here set out the rationale for and aimed to
55 predict future outcomes using model development and validation approaches. The lack of scientific attention given to this topic is
56 surprising given the dearth of literature advocating for such research. The papers identified and reviewed here, did in fact conduct
57 analyses to this effect, but only due to the fortuitous nature of the selected timepoints, and intervals between the activities of MRI
58 scanning and neuropsychological testing. Despite an extensive search strategy, evidence with which to answer the current research
59 question was extremely limited, with the major finding being a severe lack of studies in this area. The primary result of the review
60 must therefore be viewed as a need for further research in this very important research area, with study designs that directly tackle
61 the need for outcome prediction in these cohorts.

62 The reason for this brevity of research in this field is unclear. Whilst our systematic search strategy was extensive, there were also
63 difficulties in identifying papers due to poor reporting practices. For instance, for some of the studies where the full text was
64 assessed, the timing of MRI in relation to assessment was ambiguous or unclear [47-50, 55]. Factors affecting the number of
65 research articles in this area could include previous focus on survival, where increasing survival rates are now placing a greater
66 need for research on late effects. It is important to also consider that neurocognitive effects are also only one of many potential
67 late effects experienced by this population [56, 57].

68 Research in this area may also be impacted by the availability of clinical data with which to carry out this research. For children
69 with pediatric brain tumours, there is an abundance of clinical MRI, with medical imaging required for vital for tumour detection
70 and diagnosis, surgical and radiotherapy planning, and monitoring of treatment response and recurrence of disease. But this is not
71 necessarily echoed in access to neurocognitive assessment – testing is performed based upon clinical need or clinical trial protocol
72 for instance, and thus this limits available retrospective datasets. This data, also comes from a heterogeneous cohort, with these
73 children facing heterogenous brain injuries as a result of their disease and treatment. Identifying homogenous patient groups
74 inevitably results in the smaller sample sizes seen in the current studies. Overall, these factors are liable to impact the quantity of
75 research studies in this field.

76 Whilst number of studies was limited, the quality of existing studies was also a significant issue. In the reporting quality
77 assessment (using the REMARK checklist [45, 46]) identified studies did not meet important criteria for development of
78 prognostic markers. Specifically, studies failed to conduct additional analyses necessary for this development, such as sensitivity
79 or 'added-value' analyses – although this was likely due to limited sample sizes, therefore lacking statistical power necessary for
80 these additional analyses. Studies are typically involving “retrospective, monocentric study investigating a pediatric disease with
81 low annual incidence” [54] however future work will require larger sample sizes than those of the studies presented here. To note,
82 the checklist comments on a number of items pertaining to model building and multivariate analyses, which were not conducted in
83 the current studies.

84 Overall, the findings from the reviewed research are limited – they have limited sample sizes and are rated as low quality in terms
85 of prediction studies. Without proper validation and replication, the quality and impact of any conclusions must be viewed as
86 limited and/or potentially spurious. However, the findings are briefly discussed here in terms of wider literature. This should be
87 seen in the context of guiding hypothesis-driven future research and/or promoting future validation and/or replication of these
88 findings.

89 Summary of Findings of Reviewed Studies

90 Cerebellar Damage: Given common posterior fossa presentation in pediatric brain tumours, it is unsurprising that studies
91 in this review a-priori selected regions of interest within cerebellar structures and related fibre projections from this region.
92 Damage to these circuits predicted outcomes [51], with lesions to the median cerebellar regions common in cognitively impaired
93 patients [54]. Studies of contemporaneous MRI and neuropsychology measures have found similar. Horská and colleagues [58]
94 found a decrease in vermis volumes over a 6-month period were significantly related to radiation dose, and final volume after this
95 period related to neuropsychological measures of motor speed. Significant recent evidence suggests that the posterior cerebellar
96 lobes are key in maintain cognitive performance [59], and animal models suggest that intact cerebellar activity is required to
97 enable typical developmental trajectories of cognitive abilities (in mice) [60]. Essentially, the cerebellum plays as an integral node
98 in many distributed neural circuits that underpin multiple cognitive functions [61, 62]. Radical cerebellar resection has also been
99 associated with extensive WM microstructure changes across the brain [63]. Overall, it is unsurprising that damage to cerebellar
100 regions (through injury and treatment effects) may lead to multiple cognitive morbidities.

101 WM damage: Riggs, Bouffet [53] argued that global measures of WM may be indicative of general injury and thus
102 correlate well with general ability, however, integrity of discrete tracts (such as the UF) may be a better predictor of specific
103 cognitive abilities – in this case memory. Previous reviews of cross-sectional research suggests a model where disorganised WM
104 microstructure is related to poorer cognitive abilities, especially processing speed and memory deficits [22], by indicating that this

35 'damage-related impairment' is established early, and therefore WM microstructure is a potential biomarker to predict later
36 impairment. Both preclinical and patient studies suggest a loss of both GM and WM volume, and failure of normal WM gain in
37 pediatric brain tumour survivors [15]. There are multiple mechanisms of WM damage; hydrocephalous having direct neurotoxic
38 effects on periventricular WM due to decreased perfusion and oedema [64] or intragenic effect of adjunct therapy (chemo and
39 radiotherapy) as measurable by reduced volume and alterations to microstructural properties and failure of expected WM
40 development [49, 65]. WM damage is likely non-transient, in non-irradiated patients 15 years after diagnosis, FA measures are
41 reduced and are associated with impaired cognitive flexibility [66]. What is apparent is that, across treatment and disease effects,
42 the subsequent WM injury is relevant to poor outcomes, including emotion, cognition, and behaviour [13, 49, 67].

13 **Recommendations for Future Research**

14 Limited longitudinal studies

15 The biggest limitation of the current research field is the lack of longitudinal research answering this research question. Whilst
16 there have been multiple studies understanding the contemporaneous neuroanatomical substrates of poor neuropsychological
17 outcomes in pediatric brain tumours, from acutely post treatment to very long-term survivors, these have not translated into
18 similarly large body of work understanding long-term risk (as highlighted by our findings) of cognitive morbidity. Further
19 longitudinal research is needed to assess whether the contemporaneous neuroanatomical substrates of long-term impairment are in
20 fact predictive in the context of longitudinal studies.

21 These longitudinal studies would also provide an opportunity to disentangle the developmental and age-related effects on this
22 prediction-task. For several of the measures highlighted in this review (FA/MD etc.) there are known developmental trajectories
23 [68] which will necessarily interact with disease-related changes. There is also likely to be unique effects of brain insult, across
24 tumour growth, and treatment related injury at different ages, resulting in varying levels of long-term impairments [69]. The field
25 will need to rely upon longitudinal studies (with sufficient sample size/statistical power) that can sufficiently disentangle these
26 interactions.

27 Study Variables: Timing

28 There are two important timings to consider for the field moving forward to truly provide the most clinical impact moving
29 forward. Firstly, the time between 'predictive' MRI and neurocognitive assessment. Across the reported studies, this was
30 extremely short, limited to less than a year in most cases. This is potentially less useful clinically, where predictions of outcomes
31 further out (2years, 5years etc) may be of greater impact, especially in cases where the gap between them and their peers grow
32 with the failure to 'keep up'. However, given that the reported studies did not set out to develop prognostic models, this is
33 unsurprising, and unfair to judge them so. The second important timing to consider is the time between diagnosis and 'predictive'
34 MRI. In order for this predictive information to be useful for patient management and treatment planning, this interval needs to be
35 short, especially given the urgency under which these patients need to receive potentially life-saving care.

36 There is no consensus on the optimal timing of MR imaging to use for predictive purposes. Selection of which MRI is likely to be
37 most predictive (in terms of reliability, accuracy etc.) will not be trivial for future research. There is significant evidence to
38 suggest that the treatment effects of injury are damaging to the still-developing brain and thus post treatment MRI may hold the
39 complete picture of brain structural damage which lays the scaffold for future cognitive impairment. These scans may however
40 come much later in the disease course and, as the timing of the MRI used for prediction increases further from the diagnostic scan,
41 it is increasingly possible that the outcome of interest (cognitive morbidities) has already presented, and thus prediction is not
42 useful (as the observation and/or measurement of the presenting difficulties is inherently the best predictor at that time point).
43 There is also the rationale of aiming for earliest prediction possible, to best enable early neuropsychological intervention to
44 support better outcomes for these children. These children undergo MRI scanning at a number of timepoints in their disease
45 course (e.g. diagnostic imaging, pre- and post-surgical evaluation, progression monitoring etc), and so there is significant data for
46 potential retrospective studies to investigate effect of MRI timing on prediction. Direct comparisons between models using MRI
47 from different timepoints will be meaningful to elicit after which events (i.e., diagnosis, tumour growth, treatment etc.) damage
48 has been sufficient to indicate future cognitive morbidities. This will be challenging due to potential differences in MRI scans
49 between events (i.e., initial diagnostic MRI at a tertiary hospital versus post-treatment MRI at a specialist centre).

50 However, it is important to consider timing of both MRI and neuropsychological assessment in the framework of predicting
51 outcomes. There may be consolidation periods post-surgery that impact outcome measurement over time, and thus research also
52 needs to be clear in the timing of outcome measurement and / or study endpoint.

53 Added Value of MRI

54 One limitation of the current state of the research literature in this field is that the added value of MRI in prediction has not been
55 established, above and beyond existing approaches. No reviewed studies assessed existing risk factors in a multivariate analysis to
56 test the relative contributions, and therefore added value, of early MRI in predicting future neurobehavioral morbidities. However,
57 Partanen et. al. reported that none of the medical or treatment variables that they tested predicted change in IQ scores over time

58 [52]. This is despite these medical variables (Neurological Predictor Scale and presence of cerebellar mutism syndrome)
59 predicting acute/contemporaneous neuropsychology outcomes, and MRI-derived measures of baseline WM injury being
60 significantly related with outcomes [52]. This is limited evidence to support the incremental validity of MRI as a predictor of
61 long-term outcomes. Future studies should ensure to test for unique and additional predictive power offered by quantitative MRI
62 variables

63 *Study Variables: Approach to ROIs*

64 Across the studies reviewed here two conducted analyses in regions-of-interest (ROIs) directly related to sites of brain insult in
65 these patients [51, 52], one in ROIs related to the cognitive comorbidity under investigation [53], and only one investigating
66 characteristics of the lesion itself [54]. This does not consider how the wider brain network may be influenced by the brain
67 tumour, and this information may explain/predict additional variance in outcomes. For instance, in paediatric neurological
68 disorders/syndromes, differences in brain morphometry or connectivity have been found beyond the site of pathology (i.e.
69 paediatric epilepsy [70]) or in the absence of frank pathology (i.e. mild paediatric TBI [71], MRI-negative epilepsy [72]).
70 Disconnectome symptom mapping, shows that non-homologous lesions to the same brain network can generate the same
71 cognitive sequelae in terms of deficits. [73]. Many compensatory and ‘rerouting’ models of functional brain activity post injury
72 suggest that regions beyond the focal lesion may explain some sparing of cognitive abilities (another important factor in predicting
73 endpoint neurobehavioral morbidities). These findings all show that disparate, diffuse, and non-lesioned changes to the brain,
74 including tissue which may be typically thought of as ‘spared’, could also explain variance in neurobehavioral morbidities.
75 Connectivity approaches to MRI have shown utility in contemporaneous measurements of MRI and neuropsychology [74, 75].
76 These neurobiological effects of injury beyond the focal lesion may provide further prognostic information towards the aim of a
77 predictive model, however, to test a greater number of regions larger sample sizes will be necessary to accurately estimate
78 statistical models across many more ROIs. This highlights one of the key challenges for future studies in this field being data
79 collection.

63 **Limitations of Review**

64 It should be noted that, despite an extensive search, no study explicitly investigated the research question of whether MRI could
65 be used for long term prediction of neurocognitive outcomes in pediatric brain tumour patients. Described studies were reviewed
66 here due to non-primary analyses which fulfilled inclusion criteria, and therefore it may be the case that other studies with such
67 analyses may have been missed in the review process (for instance if these secondary analyses were not mentioned in the
68 abstract). To address this, we erred on the side of caution in reviewing abstracts, using full-text review as a method to identify
69 these relevant secondary analyses.

63 **Conclusion**

64 As early as 2008, it was proposed that to truly balance the aggressiveness of treatment for childhood CNS tumours, against the
65 relative quality of life due to cognitive impairment, an important factor is knowing the likelihood of any one individual
66 experiencing neurocognitive impairment [12]. This individualised risk is key in purported models of monitoring and managing of
67 neurocognitive functioning in children with brain tumours [76]. There has also been significant work in the field of pediatric brain
68 tumours proposing developmental cognitive neuroscience models of late effects in survivors [12, 22, 77, 78]. These models, built
69 on contemporaneous measures of cognition and brain development, alongside cross-sectional data, are inherently limited.
70 Knowing individualised risk of long-term cognitive morbidity ahead of time would have significant clinical impact; to inform
71 clinical management, prioritise resources/support, and reduce uncertainty for families. Overall, there exists plenty clinical
72 reasoning to prompt scientific enthusiasm and attention for this topic.

63 However, despite these early calls for prediction, and models with which to guide these predictive studies, this systematic review
64 highlights that the number of truly predictive studies (requiring a period between predictive features and long-term outcomes) is
65 still limited. In conclusion, Given the increased number of adult survivors of childhood brain tumours, the poorer long-term
66 cognitive, educational and employment outcomes [10, 13, 14] and the significant burden this represents to patients, families and
67 healthcare, work now needs to be completed to integrate predictive data into these models, which will expand their explanatory
68 value and utility to clinical practice. This will be an important next step in delivering further clinical impact for this patient group.

63 Given the great potential that MRI provides in investigating neurobiological effects of disease and treatment at the individual-
64 level, the plethora of multimodal imaging available in these clinical populations and finally the positive clinical benefit this could
65 offer, there is exciting opportunities for this type of research.

63 **Data Availability**

64 Data extracted from included studies is publicly available and found (in its entirety) in Table 2. Lists of reviewed studied, at each
65 stage of the PRISMA flowchart are available from the authors upon reasonable request.

10 *Acknowledgments*

11 DGK is funded by a post-doctoral award from Aston University College of Health and Life Sciences, awarded to JN & DGK.

12

13

References

- 14 1. Miller, K.D., L. Nogueira, T. Devasia, A.B. Mariotto, K.R. Yabroff, A. Jemal, J. Kramer, and R.L. Siegel, *Cancer treatment and survivorship statistics, 2022*. CA Cancer J Clin, 2022. **72**(5): p. 409-436.
- 15 2. Phillips, S.M., L.S. Padgett, W.M. Leisenring, K.K. Stratton, K. Bishop, K.R. Krull, C.M. Alfano, T.M.
- 16 3. Gibson, J.S. de Moor, D.B. Hartigan, G.T. Armstrong, L.L. Robison, J.H. Rowland, K.C. Oeffinger, and A.B. Mariotto, *Survivors of childhood cancer in the United States: prevalence and burden of morbidity*. Cancer Epidemiol Biomarkers Prev, 2015. **24**(4): p. 653-63.
- 17 4. American Cancer Society, *Cancer Facts & Figures 2014*, A.C. Society, Editor. 2014, American Cancer Society: Atlanta.
- 18 5. Ward, E., C. DeSantis, A. Robbins, B. Kohler, and A. Jemal, *Childhood and adolescent cancer statistics, 2014*. CA Cancer J Clin, 2014. **64**(2): p. 83-103.
- 19 6. Tabash, M.A., *Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in the United States; SEER-based analysis*. J Neurol Sci, 2019. **400**: p. 148-152.
- 20 7. Ramaswamy, V. and M.D. Taylor, *Medulloblastoma: From Myth to Molecular*. J Clin Oncol, 2017. **35**(21): p. 2355-2363.
- 21 8. Gatta, G., G. Zigon, R. Capocaccia, J.W. Coebergh, E. Desandes, P. Kaatsch, G. Pastore, R. Peris-Bonet, C.A. Stiller, and E.W. Group, *Survival of European children and young adults with cancer diagnosed 1995-2002*. Eur J Cancer, 2009. **45**(6): p. 992-1005.
- 22 9. Prevention, C.f.D.C., *Declines in cancer death rates among children and adolescents in the United States, 1999-2014*. 2016.
- 23 10. Wang, Y., A.P.Y. Liu, T.M. Lee, W.H.S. Wong, D.Y.T. Fong, L.K. Leung, M.M.K. Shing, D.T. Ku, G.C. Chan, and W.W. Tso, *Neurobehavioral Impairment in Pediatric Brain Tumor Survivors: A Meta-Analysis*. Cancers (Basel), 2022. **14**(13).
- 24 11. Maddrey, A.M., J.A. Bergeron, E.R. Lombardo, N.K. McDonald, A.F. Mulne, P.D. Barenberg, and D.C. Bowers, *Neuropsychological performance and quality of life of 10 year survivors of childhood medulloblastoma*. J Neurooncol, 2005. **72**(3): p. 245-53.
- 25 12. Palmer, S.L., O. Goloubeva, W.E. Reddick, J.O. Glass, A. Gajjar, L. Kun, T.E. Merchant, and R.K. Mulhern, *Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis*. Journal of Clinical Oncology, 2001. **19**(8): p. 2302-2308.
- 26 13. Askins, M.A. and B.D. Moore, 3rd, *Preventing neurocognitive late effects in childhood cancer survivors*. J Child Neurol, 2008. **23**(10): p. 1160-71.
- 27 14. Lassaletta, A., E. Bouffet, D. Mabbott, and A.V. Kulkarni, *Functional and neuropsychological late outcomes in posterior fossa tumors in children*. Childs Nerv Syst, 2015. **31**(10): p. 1877-90.
- 28 15. Devine, K.A., S. Christen, R.L. Mulder, M.C. Brown, L.M. Ingerski, L. Mader, E.J. Potter, C. Sleurs, A.S. Viola, S. Waern, L.S. Constine, M.M. Hudson, L.C.M. Kremer, R. Skinner, G. Michel, J. Gilleland Marchak, F.S.M. Schulte, and G. International Guidelines Harmonization Group Psychological Late Effects, *Recommendations for the surveillance of education and employment outcomes in survivors of childhood, adolescent, and young adult cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group*. Cancer, 2022. **128**(13): p. 2405-2419.
- 29 16. Al Dahhan, N.Z., E. Cox, B.J. Nieman, and D.J. Mabbott, *Cross-translational models of late-onset cognitive sequelae and their treatment in pediatric brain tumor survivors*. Neuron, 2022. **110**(14): p. 2215-2241.
- 30 17. Hardy, K.K., M.M. Hudson, and K.R. Krull, *Life-Altering Consequences of Neurocognitive Impairment in Survivors of Pediatric Cancer*. J Clin Oncol, 2021. **39**(16): p. 1693-1695.
- 31 18. Willard, V.W., K.S. Berlin, H.M. Conklin, and T.E. Merchant, *Trajectories of psychosocial and cognitive functioning in pediatric patients with brain tumors treated with radiation therapy*. Neuro Oncol, 2019. **21**(5): p. 678-685.
- 32 19. Sharkey, C.M., L.L. Mullins, A.H. Clawson, A. Gioia, M.A.W. Hawkins, J.M. Chaney, K.S. Walsh, and K.K. Hardy, *Assessing neuropsychological phenotypes of pediatric brain tumor survivors*. Psychooncology, 2021. **30**(8): p. 1366-1374.
- 33 20. Major, N., N.A. Patel, J. Bennett, E. Novakovic, D. Poloni, M. Abraham, N.J. Brown, J.L. Gendreau, R. Sahyouni, and J. Loya, *The Current State of Radiotherapy for Pediatric Brain Tumors: An Overview of Post-Radiotherapy Neurocognitive Decline and Outcomes*. J Pers Med, 2022. **12**(7).
- 34 21. Ajithkumar, T., S. Price, G. Horan, A. Burke, and S. Jefferies, *Prevention of radiotherapy-induced neurocognitive dysfunction in survivors of paediatric brain tumours: the potential role of modern imaging and radiotherapy techniques*. Lancet Oncol, 2017. **18**(2): p. e91-e100.
- 35 22. Peterson, R.K. and T.Z. King, *A systemic review of pediatric neuropsychological outcomes with proton versus photon radiation therapy: A call for equity in access to treatment*. J Int Neuropsychol Soc, 2022: p. 1-14.

- 70 22. Wauters, M., A. Uyttebroeck, L. De Waele, C. Sleurs, and S. Jacobs, *Neuroimaging Biomarkers and*
71 *Neurocognitive Outcomes in Pediatric Medulloblastoma Patients: a Systematic Review*. *Cerebellum*, 2021.
72 **20**(3): p. 462-480.
- 73 23. Oyefiade, A., I. Paltin, C.R. De Luca, K.K. Hardy, D.R. Grosshans, M. Chintagumpala, D.J. Mabbott, and
74 L.S. Kahalley, *Cognitive Risk in Survivors of Pediatric Brain Tumors*. *J Clin Oncol*, 2021. **39**(16): p. 1718-
75 1726.
- 76 24. Palmer, S.L., *Neurodevelopmental impact on children treated for medulloblastoma: a review and proposed*
77 *conceptual model*. *Dev Disabil Res Rev*, 2008. **14**(3): p. 203-10.
- 78 25. Wolfe, K.R., A. Madan-Swain, and R.K. Kana, *Executive dysfunction in pediatric posterior fossa tumor*
79 *survivors: a systematic literature review of neurocognitive deficits and interventions*. *Dev Neuropsychol*,
30 2012. **37**(2): p. 153-75.
- 31 26. King, T.Z., A.S. Ailion, M.E. Fox, and S.M. Hufstetler, *Neurodevelopmental model of long-term outcomes of*
32 *adult survivors of childhood brain tumors*. *Child Neuropsychol*, 2019. **25**(1): p. 1-21.
- 33 27. Marusak, H.A., A.S. Iadipaolo, F.W. Harper, F. Elrahal, J.W. Taub, E. Goldberg, and C.A. Rabinak,
34 *Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity*
35 *framework to understanding cognitive, behavioral, and emotional outcomes*. *Neuropsychol Rev*, 2018. **28**(2):
36 p. 123-175.
- 37 28. King, A.A., K. Seidel, C. Di, W.M. Leisenring, S.M. Perkins, K.R. Krull, C.A. Sklar, D.M. Green, G.T.
38 Armstrong, L.K. Zeltzer, E. Wells, M. Stovall, N.J. Ullrich, K.C. Oeffinger, L.L. Robison, and R.J. Packer,
39 *Long-term neurologic health and psychosocial function of adult survivors of childhood*
40 *medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study*. *Neuro Oncol*, 2017. **19**(5): p.
41 689-698.
- 42 29. de Rooter, M.A., R. van Mourik, A.Y. Schouten-van Meeteren, M.A. Grootenhuis, and J. Oosterlaan,
43 *Neurocognitive consequences of a paediatric brain tumour and its treatment: a meta-analysis*. *Dev Med Child*
44 *Neurol*, 2013. **55**(5): p. 408-17.
- 45 30. Nathan, P.C., S.K. Patel, K. Dilley, R. Goldsby, J. Harvey, C. Jacobsen, N. Kadan-Lottick, K. McKinley, A.K.
46 Millham, I. Moore, M.F. Okcu, C.L. Woodman, P. Brouwers, F.D. Armstrong, and C. Children's Oncology
47 Group Long-term Follow-up Guidelines Task Force on Neurocognitive/Behavioral Complications After
48 Childhood, *Guidelines for identification of, advocacy for, and intervention in neurocognitive problems in*
49 *survivors of childhood cancer: a report from the Children's Oncology Group*. *Arch Pediatr Adolesc Med*,
50 2007. **161**(8): p. 798-806.
- 51 31. Krull, K.R., S. Minoshima, M. Edelmann, B. Morris, N.D. Sabin, T.M. Brinkman, G.T. Armstrong, L.L.
52 Robison, M.M. Hudson, and B. Shulkin, *Regional brain glucose metabolism and neurocognitive function in*
53 *adult survivors of childhood cancer treated with cranial radiation*. *J Nucl Med*, 2014. **55**(11): p. 1805-10.
- 54 32. Carpentieri, S.C., D.P. Waber, S.L. Pomeroy, R.M. Scott, L.C. Goumnerova, M.W. Kieran, A.L. Billett, and
55 N.J. Tarbell, *Neuropsychological functioning after surgery in children treated for brain tumor*. *Neurosurgery*,
56 2003. **52**(6): p. 1348-56; discussion 1356-7.
- 57 33. Taiwo, Z., S. Na, and T.Z. King, *The Neurological Predictor Scale: A predictive tool for long-term core*
58 *cognitive outcomes in survivors of childhood brain tumors*. *Pediatr Blood Cancer*, 2017. **64**(1): p. 172-179.
- 59 34. Levitch, C.F., A.A. Holland, J. Bledsoe, S.Y. Kim, M. Barnett, S. Ramjan, and S.A. Sands, *Comparison of*
60 *neuropsychological functioning in pediatric posterior fossa tumor survivors: Medulloblastoma, low-grade*
61 *astrocytoma, and healthy controls*. *Pediatr Blood Cancer*, 2022. **69**(2): p. e29491.
- 62 35. Micklewright, J.L., T.Z. King, R.D. Morris, and N. Krawiecki, *Quantifying pediatric neuro-oncology risk*
63 *factors: development of the neurological predictor scale*. *J Child Neurol*, 2008. **23**(4): p. 455-8.
- 64 36. Papazoglou, A., T.Z. King, R.D. Morris, and N. Krawiecki, *Parent report of attention problems predicts later*
65 *adaptive functioning in children with brain tumors*. *Child Neuropsychol*, 2009. **15**(1): p. 40-52.
- 66 37. King, T.Z. and S. Na, *Cumulative neurological factors associated with long-term outcomes in adult survivors*
67 *of childhood brain tumors*. *Child Neuropsychol*, 2016. **22**(6): p. 748-60.
- 68 38. Kautiainen, R.J., S.D. Na, and T.Z. King, *Neurological predictor scale is associated with academic*
69 *achievement outcomes in long-term survivors of childhood brain tumors*. *J Neurooncol*, 2019. **142**(1): p. 193-
70 201.
- 71 39. Bae, D., V.V. Mlc, and C.E. Catsman-Berrevoets, *Preoperative prediction of postoperative cerebellar mutism*
72 *syndrome. Validation of existing MRI models and proposal of the new Rotterdam pCMS prediction model*.
73 *Childs Nerv Syst*, 2020. **36**(7): p. 1471-1480.
- 74 40. Kesler, S.R., C. Sleurs, B.C. McDonald, S. Deprez, E. van der Plas, and B.J. Nieman, *Brain Imaging in*
75 *Pediatric Cancer Survivors: Correlates of Cognitive Impairment*. *J Clin Oncol*, 2021. **39**(16): p. 1775-1785.
- 76 41. Baker, S. and Y. Kandasamy, *Machine learning for understanding and predicting neurodevelopmental*
77 *outcomes in premature infants: a systematic review*. *Pediatr Res*, 2022: p. 1-7.

- 28 42. Li, X., X. Wang, L. Su, X. Hu, and Y. Han, *Sino Longitudinal Study on Cognitive Decline (SILCODE):*
29 *protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to*
30 *mild cognitive impairment in individuals with subjective cognitive decline.* *BMJ Open*, 2019. **9**(7): p. e028188.
- 31 43. Page, M.J., J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M.
32 Tetzlaff, E.A. Akl, S.E. Brennan, R. Chou, J. Glanville, J.M. Grimshaw, A. Hrobjartsson, M.M. Lalu, T. Li,
33 E.W. Loder, E. Mayo-Wilson, S. McDonald, L.A. McGuinness, L.A. Stewart, J. Thomas, A.C. Tricco, V.A.
34 Welch, P. Whiting, and D. Moher, *The PRISMA 2020 statement: an updated guideline for reporting*
35 *systematic reviews.* *Syst Rev*, 2021. **10**(1): p. 89.
- 36 44. Ostrom, Q.T., G. Cioffi, K. Waite, C. Kruchko, and J.S.J.N.-o. Barnholtz-Sloan, *CBTRUS statistical report:*
37 *primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018.* 2021.
38 **23**(Supplement_3): p. iii1-iii105.
- 39 45. McShane, L.M., D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark, *Reporting*
40 *recommendations for tumor marker prognostic studies (REMARK).* *Journal of the National Cancer Institute*,
41 2005. **97**(16): p. 1180-1184.
- 42 46. Sauerbrei, W., S.E. Taube, L.M. McShane, M.M. Cavenagh, and D.G. Altman, *Reporting Recommendations*
43 *for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration.* *J Natl Cancer*
44 *Inst*, 2018. **110**(8): p. 803-811.
- 45 47. Aukema, E.J., M.W. Caan, N. Oudhuis, C.B. Majoie, F.M. Vos, L. Reneman, B.F. Last, M.A. Grootenhuys,
46 and A.Y. Schouten-van Meeteren, *White matter fractional anisotropy correlates with speed of processing and*
47 *motor speed in young childhood cancer survivors.* *Int J Radiat Oncol Biol Phys*, 2009. **74**(3): p. 837-43.
- 48 48. Mulhern, R.K., S.L. Palmer, W.E. Reddick, J.O. Glass, L.E. Kun, J. Taylor, J. Langston, and A. Gajjar, *Risks*
49 *of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss.* *J*
50 *Clin Oncol*, 2001. **19**(2): p. 472-9.
- 51 49. Reddick, W.E., D.J. Taghipour, J.O. Glass, J. Ashford, X.P. Xiong, S.J. Wu, M. Bonner, R.B. Khan, and H.M.
52 Conklin, *Prognostic Factors that Increase the Risk for Reduced White Matter Volumes and Deficits in*
53 *Attention and Learning for Survivors of Childhood Cancers.* *Pediatric Blood & Cancer*, 2014. **61**(6): p. 1074-
54 1079.
- 55 50. Tso, W.W.Y., E.S.K. Hui, T.M.C. Lee, A.P.Y. Liu, P. Ip, V. Vardhanabhuti, K.K.F. Cheng, D.Y.T. Fong,
56 D.H.F. Chang, F.K.W. Ho, K.M. Yip, D.T.L. Ku, D.K.L. Cheuk, C.W. Luk, M.K. Shing, L.K. Leung, P.L.
57 Khong, and G.C. Chan, *Brain Microstructural Changes Associated With Neurocognitive Outcome in*
58 *Intracranial Germ Cell Tumor Survivors.* *Front Oncol*, 2021. **11**: p. 573798.
- 59 51. Liguoro, I., E. Passone, T. Zilli, M. Maieron, M.C. De Colle, M. Skrap, V. Dolcemascolo, G. Sommariva, P.
60 Cogo, and B. Tomasino, *Possible association between the integrity of cerebellar pathways and neurocognitive*
61 *performance in children with posterior fossa tumors.* *Pediatr Blood Cancer*, 2020. **67**(9): p. e28538.
- 62 52. Partanen, M., E. Bouffet, S. Laughlin, D. Strother, J. Hukin, J. Skocic, K. Szulc-Lerch, and D.J. Mabbott,
63 *Early changes in white matter predict intellectual outcome in children treated for posterior fossa tumors.*
64 *Neuroimage Clin*, 2018. **20**: p. 697-704.
- 65 53. Riggs, L., E. Bouffet, S. Laughlin, N. Laperriere, F. Liu, J. Skocic, N. Scantlebury, F. Wang, N.J. Schoenhoff,
66 D. Strother, J. Hukin, C. Fryer, D. McConnell, and D.J. Mabbott, *Changes to memory structures in children*
67 *treated for posterior fossa tumors.* *J Int Neuropsychol Soc*, 2014. **20**(2): p. 168-80.
- 68 54. Zilli, T., V. Dolcemascolo, E. Passone, M. Maieron, M.C. De Colle, M. Skrap, T. Ius, I. Liguoro, M.
69 Venchiarutti, P. Cogo, and B. Tomasino, *A multimodal approach to the study of children treated for posterior*
70 *fossa tumor: A review of the literature and a pilot study.* *Clin Neurol Neurosurg*, 2021. **207**: p. 106819.
- 71 55. Kline, C., S. Stoller, L. Byer, D. Samuel, J.M. Lupo, M.A. Morrison, A.M. Rauschecker, P. Nedelec, W. Faig,
72 D.B. Dubal, H.J. Fullerton, and S. Mueller, *An Integrated Analysis of Clinical, Genomic, and Imaging*
73 *Features Reveals Predictors of Neurocognitive Outcomes in a Longitudinal Cohort of Pediatric Cancer*
74 *Survivors, Enriched with CNS Tumors (Rad ART Pro).* *Front Oncol*, 2022. **12**: p. 874317.
- 75 56. Rey-Casserly, C. and T.J.C.o.i.p. Diver, *Late effects of pediatric brain tumors.* 2019. **31**(6): p. 789-796.
- 76 57. Alemany, M., R. Velasco, M. Simó, and J.J.N.-O.P. Bruna, *Late effects of cancer treatment: consequences for*
77 *long-term brain cancer survivors.* 2021. **8**(1): p. 18-30.
- 78 58. Horska, A., A. Laclair, M. Mohamed, C.T. Wells, T. McNutt, K.J. Cohen, M. Wharam, E.M. Mahone, and W.
79 Kates, *Low cerebellar vermis volumes and impaired neuropsychologic performance in children treated for*
80 *brain tumors and leukemia.* *AJNR Am J Neuroradiol*, 2010. **31**(8): p. 1430-7.
- 81 59. Hoang, D.H., A. Pagnier, K. Guichardet, F. Dubois-Teklali, I. Schiff, G. Lyard, E. Cousin, and A. Krainik,
82 *Cognitive disorders in pediatric medulloblastoma: what neuroimaging has to offer.* *J Neurosurg Pediatr*,
83 2014. **14**(2): p. 136-44.
- 84 60. Badura, A., J.L. Verpeut, J.W. Metzger, T.D. Pereira, T.J. Pisano, B. Deverett, D.E. Bakshinskaya, and S.S.
85 Wang, *Normal cognitive and social development require posterior cerebellar activity.* *Elife*, 2018. **7**.

- 36 61. Clark, S.V., E.S. Semmel, H.A. Aleksonis, S.N. Steinberg, and T.Z. King, *Cerebellar-Subcortical-Cortical*
37 *Systems as Modulators of Cognitive Functions*. *Neuropsychol Rev*, 2021. **31**(3): p. 422-446.
- 38 62. Schmahmann, J.D., *The cerebellum and cognition*. *Neurosci Lett*, 2019. **688**: p. 62-75.
- 39 63. Gomes, C.A., K.M. Steiner, N. Ludolph, T. Spisak, T.M. Ernst, O. Mueller, S.L. Goricke, F. Labrenz, W. Ilg,
40 N. Axmacher, and D. Timmann, *Resection of cerebellar tumours causes widespread and functionally relevant*
41 *white matter impairments*. *Hum Brain Mapp*, 2021. **42**(6): p. 1641-1656.
- 42 64. Moberget, T., S. Andersson, T. Lundar, B.J. Due-Tonnessen, A. Heldal, T. Endestad, and L.T. Westlye, *Long-*
43 *term supratentorial brain structure and cognitive function following cerebellar tumour resections in*
44 *childhood*. *Neuropsychologia*, 2015. **69**: p. 218-31.
- 45 65. Witzmann, K., F. Raschke, and E.G.C. Troost, *MR Image Changes of Normal-Appearing Brain Tissue after*
46 *Radiotherapy*. *Cancers (Basel)*, 2021. **13**(7).
- 47 66. Billiet, T., I. Elens, C. Sleurs, A. Uyttebroeck, R. D'Hooge, J. Lemiere, and S. Deprez, *Brain Connectivity and*
48 *Cognitive Flexibility in Nonirradiated Adult Survivors of Childhood Leukemia*. *J Natl Cancer Inst*, 2018.
49 **110**(8): p. 905-913.
- 50 67. Raghubar, K.P., E.M. Mahone, K.O. Yeates, K.M. Cecil, M. Makola, and M.D. Ris, *Working memory and*
51 *attention in pediatric brain tumor patients treated with and without radiation therapy*. *Child Neuropsychol*,
52 2017. **23**(6): p. 642-654.
- 53 68. Krogsrud, S.K., A.M. Fjell, C.K. Tamnes, H. Grydeland, L. Mork, P. Due-Tonnessen, A. Bjornerud, C.
54 Sampaio-Baptista, J. Andersson, H. Johansen-Berg, and K.B. Walhovd, *Changes in white matter*
55 *microstructure in the developing brain--A longitudinal diffusion tensor imaging study of children from 4 to*
56 *11 years of age*. *Neuroimage*, 2016. **124**(Pt A): p. 473-486.
- 57 69. Jones, R.M. and S.S. Pattwell, *Future considerations for pediatric cancer survivorship: Translational*
58 *perspectives from developmental neuroscience*. *Dev Cogn Neurosci*, 2019. **38**: p. 100657.
- 59 70. Boutzoukas, E.M., J. Crutcher, E. Somoza, L.N. Sepeta, X. You, W.D. Gaillard, G.L. Wallace, and M.M.
60 Berl, *Cortical thickness in childhood left focal epilepsy: Thinning beyond the seizure focus*. *Epilepsy Behav*,
61 2020. **102**: p. 106825.
- 62 71. King, D.J., K.R. Ellis, S. Seri, and A.G. Wood, *A systematic review of cross-sectional differences and*
63 *longitudinal changes to the morphometry of the brain following paediatric traumatic brain injury*.
64 *Neuroimage Clin*, 2019. **23**: p. 101844.
- 65 72. Zelko, F.A., H.R. Pardoe, S.R. Blackstone, G.D. Jackson, and A.T. Berg, *Regional brain volumes and*
66 *cognition in childhood epilepsy: does size really matter?* *Epilepsy Res*, 2014. **108**(4): p. 692-700.
- 67 73. Foulon, C., L. Cerliani, S. Kinkingnéhun, R. Levy, C. Rosso, M. Urbanski, E. Volle, and M. Thiebaut de
68 Schotten, *Advanced lesion symptom mapping analyses and implementation as BCBtoolkit*. *Gigascience*, 2018.
69 **7**(3): p. 1-17.
- 70 74. Sleurs, C., J. Blommaert, D. Batalle, M. Verly, S. Sunaert, R. Peeters, J. Lemiere, A. Uyttebroeck, and S.
71 Deprez, *Cortical thinning and altered functional brain coherence in survivors of childhood sarcoma*. *Brain*
72 *Imaging Behav*, 2021. **15**(2): p. 677-688.
- 73 75. Sleurs, C., S. Jacobs, S.J. Counsell, D. Christiaens, J.D. Tournier, S. Sunaert, K. Van Beek, A. Uyttebroeck, S.
74 Deprez, D. Batalle, and J. Lemiere, *Brain network hubs and cognitive performance of survivors of childhood*
75 *infratentorial tumors*. *Radiother Oncol*, 2021. **161**: p. 118-125.
- 76 76. Jacola, L.M., M. Partanen, J. Lemiere, M.M. Hudson, and S. Thomas, *Assessment and Monitoring of*
77 *Neurocognitive Function in Pediatric Cancer*. *J Clin Oncol*, 2021. **39**(16): p. 1696-1704.
- 78 77. Ailion, A.S., T.Z. King, L. Wang, M.E. Fox, H. Mao, R.M. Morris, and B. Crosson, *Cerebellar Atrophy in*
79 *Adult Survivors of Childhood Cerebellar Tumor*. *J Int Neuropsychol Soc*, 2016. **22**(5): p. 501-11.
- 80 78. Palmer, S.L., J.O. Glass, Y. Li, R. Ogg, I. Qaddoumi, G.T. Armstrong, K. Wright, C. Wetmore, A. Broniscer,
81 A. Gajjar, and W.E. Reddick, *White matter integrity is associated with cognitive processing in patients treated*
82 *for a posterior fossa brain tumor*. *Neuro Oncol*, 2012. **14**(9): p. 1185-93.